KalVista Pharmaceuticals (NASDAQ:KALV) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS

KalVista Pharmaceuticals (NASDAQ:KALV) released its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.04, Yahoo Finance reports.

KalVista Pharmaceuticals Stock Performance

NASDAQ:KALV opened at $12.34 on Friday. KalVista Pharmaceuticals has a one year low of $7.21 and a one year high of $16.88. The business’s 50-day simple moving average is $13.17 and its 200 day simple moving average is $12.42. The stock has a market cap of $520.60 million, a price-to-earnings ratio of -3.63 and a beta of 0.91.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on KALV shares. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday. Finally, Cantor Fitzgerald upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 26th.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,135 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $12.40, for a total value of $26,474.00. Following the transaction, the insider now directly owns 83,745 shares of the company’s stock, valued at approximately $1,038,438. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,135 shares of the stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $12.40, for a total transaction of $26,474.00. Following the transaction, the insider now owns 83,745 shares of the company’s stock, valued at approximately $1,038,438. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Christopher Yea sold 7,102 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $12.01, for a total value of $85,295.02. Following the completion of the sale, the insider now owns 84,467 shares of the company’s stock, valued at $1,014,448.67. The disclosure for this sale can be found here. Insiders sold a total of 23,452 shares of company stock worth $282,491 in the last 90 days. 12.30% of the stock is owned by corporate insiders.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.